Desrues, et al.. Soluble CD14 acts as a DAMP in human macrophages: origin and involvement in inflammatory cytokine/chemokine production.
INTRODUCTION
involvement of sCD14 has not been studied. In this work, we examined the mechanisms involved 
Neosynthesis measurement

191
Soluble CD14 neosynthesis was measured using Click-IT ® technology (Thermo-fischer 192 scientific). Macrophages were placed in RPMI 1640 medium without methionine (Gibco, 193 ThermoFisher Scientific, Saint Aubin, France). After 30 min incubation (37°C, 5% CO 2 ), Zymography assay 215 The gelatinolytic activity of secreted MMP-9 was analyzed using gelatin zymography, as 216 described previously (32). The samples were subjected to electrophoresis via 10% SDS-PAGE 217 containing 1 mg/ml of gelatin (Sigma Aldrich, Saint-Quentin Fallavier, France) under non-218 reducing conditions. After electrophoresis, the gels were washed twice with 2.5% Triton X-100, 219 rinsed with water, and incubated at 37°C overnight in reaction buffer (50 mM Tris, 5 mM CaCl 2 , 220 and 2.1 mM ZnCl 2 , pH 8.0). The gels were stained with Coomassie brilliant blue (Sigma Aldrich, 221 Saint-Quentin Fallavier, France) and de-stained in a solution of 25% ethanol and 10% acetic acid.
222
Gelatinase activity appeared as clear bands against a blue background. The molecular weights of 223 the gelatinolytic bands were estimated using a prestained protein ladder 224 Euromedex, Souffelweyersheim, France). Images of the zymograms were acquired using the Gel 225 Doc 1000 Gel Documentation System (Bio-Rad laboratories, Marnes-La -Coquette, France), and 226 both the surface and intensity of the lysis bands were quantified by densitometry using the
227
MultiGauge software (Fujifilm, Tokyo, Japan). ThermoFisher Scientific, Saint Aubin, France). The transfection reagent and siRNAs were mixed, 234 and complex formation was allowed to proceed for 5 min at room temperature before the 235 complex was added to the macrophages. After 72 hours, the cells were treated or not treated with 236 sCD14 (500 ng/ml, 24 hours) before being harvested for analysis.
238
Immunoblotting
239
Membrane-bound proteins were extracted from the macrophages by lysing the cells with RIPA 240 lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Triton-X100, 241 12 mM deoxycholate, 2 mM NaF, 1 mM Na 3 VO 4 , 2 mM PMSF, cOmplete™ EDTA-free France) antibodies were used as secondary antibodies, and proteins were detected using enhanced 255 chemiluminescence. The images were scanned with the Fujifilm LAS-3000 imager (Fujifilm, 256 Tokyo, Japan) and analyzed with the MultiGauge software (Fujifilm, Tokyo, Japan) for 257 densitometry. The intensity of the bands was normalized based on HSC-70.
259
Statistical analysis
260
The number of subjects and experiments used in each group is stated in the respective figures.
261
Statistical significance was evaluated by using the GraphPad Prism software v.6.0 (GraphPad
262
Software Inc., San Diego, CA, US). A non-parametric Mann-Whitney test was used to assess the 263 statistical significance of differences between non-CF and CF groups. A parametric ratio 264 Student's t-test was used to assess statistical significance between treatments. For each analysis, a 265 p-value <0.05 was considered to be significant.
12
RESULTS
269
Origin of sCD14 in human CF macrophages 270 
271
We previously observed the overproduction of sCD14 in the supernatant of macrophages from 272 stable adult patients with CF (29). However, plasma levels of sCD14 do not differ between stable 273 adult CF patients and healthy subjects (Fig. 1A) .
275
To elucidate the molecular mechanisms that underlie the production of the soluble form of CD14 276 in human CF macrophages, we studied several hypotheses based on the literature. It was reported 277 that sCD14 could be generated by different mechanisms, including the endocytosis of mCD14, 278 the cleavage of the GPI anchor by PI-PLC, direct proteolytic cleavage from the cell surface and 279 neosynthesis.
281
To explore the neosynthesis hypothesis, we examined the regulation of CD14 production at the 282 mRNA level in CF and non-CF macrophages. We found that CD14 mRNA levels were similar 283 between CF and non-CF macrophages (Fig. 1B) . Furthermore, pulse chase experiments with
284
Click-IT® L-Azidohomoalanin showed no differences in neosynthesis of sCD14 between non-
285
CF and CF macrophages whereas we demonstrated an increase of total sCD14 production in 286 supernatant of CF macrophages (Fig. 1C) . Thus, neosynthesis can be ruled out as a mechanism. are decreased in CF vs. non-CF macrophages (Fig. 2C) . The protease cleavage hypothesis is 296 excluded by these results.
The main hypothesis concerning sCD14 generation is the cleavage of the GPI tail by PI-PLC. We 299 investigated this hypothesis by exposing non-CF macrophages to PI-PLC (1 U/ml) with or 300 without its inhibitor, U-73122 (12.5 µM). We observed that PI-PLC significantly increased the 301 production of sCD14 by non-CF macrophages and that this effect was inhibited by U-73122 (Fig.   302   3A) . However, the treatment of CF macrophages with U-73122 did not inhibit the increased 303 secretion of sCD14 into their supernatant (Fig. 3B) . Furthermore, the expression of the PLC gene 304 does not differ between non-CF and CF macrophages (Supplemental Fig. 1G ). Indeed, participates in the production of sCD14 in non-CF macrophages but has no role in sCD14 306 overproduction from CF macrophages. To evaluate the inflammatory role of sCD14 in human non-CF macrophages, we used human 323 recombinant sCD14 (hr-sCD14), which did not affect the viability of the cells (data not shown).
325
We had to check the effect of human recombinant sCD14 on the NFκB activation, which is 326 required for cytokine/chemokine production. In fact, the mean concentration of sCD14 in CF 327 macrophage supernatants was 14.68 ng/ml per 2x10 6 cells/well (Fig. 3B) , which corresponds to 328 220 ng/ml per 30x10 6 cells, in comparison to the mean level of sCD14 observed in non-CF 14 macrophage supernatants, which was 2.35 ng/ml per 30x10 6 cells/well (Fig. 4B) . Indeed, we used 330 increasing concentrations of human recombinant sCD14 (1, 10, 100 and 500 ng/ml on 30x10 6 331 non-CF cells/well) to evaluate its inflammatory role in macrophages.
333
To determine whether sCD14 has an inflammatory effect, we investigated the production of pro-334 inflammatory cytokine/chemokine by non-CF macrophages exposed to sCD14. Treatment with 335 sCD14 significantly increased IL-1β, IL-8 and TNF-α gene expressions at 6 hours and secreted 336 levels at 24 hours in a dose-dependent manner ( Fig. 5A and 5B). The effects on gene expression 337 were maintained at 24 hours (Fig. 5A) . These results show that sCD14 could participate in 338 chronic inflammation by promoting pro-inflammatory cytokine/chemokine secretion.
339
Furthermore, sCD14 potentiates LPS-induced cytokine/chemokine production by non-CF 340 macrophages (Supplemental Fig. 2 ).
342
The NF-κB pathway is one of the pathways involved in cytokine expression. We studied NF-κB In view of the mechanisms described above, the TLR-4 receptor and its signaling pathways 385 should be involved in the effects induced by sCD14 in macrophages. To efficiently neutralize the 386 biological activity of sCD14, non-CF macrophages were pre-incubated with a CD14-neutralizing 387 antibody, resulting in decreased IL-8, TNF-α and IL-1β levels in the cell supernatants (Fig. 9 ).
388
Moreover, the pretreatment of non-CF macrophages with an antagonist of TLR-4 (LPS-RS) 16 strongly inhibited the TNF-α, IL-8 and IL-1β production induced by sCD14 (Fig. 9 ). Finally to 390 neutralize TLR4, non-CF macrophages were pre-incubated with a TLR4-neutralizing antibody, In a previous study, we observed an increase in cytokine/chemokine production in CF 402 macrophage supernatants and particularly strong secretion of sCD14 (29) It has been previously shown that sCD14 could be generated by several mechanisms, which anchor by phospholipases is also suggested to explain sCD14 release. In our study, PI-PLC 422 induced increased production of sCD14 in non-CF macrophage supernatants. The PI-PLC 423 inhibitor reversed this effect but not the sCD14 overproduction observed in CF macrophages.
424
Thus, PI-PLC participates in the production of sCD14 in non-CF macrophages but has no role in In conclusion, numerous mechanisms concerning the origin of sCD14 were considered in this 483 work, but in CF macrophages, the endocytosis/exocytosis process appears to be the main 484 mechanism involved in sCD14 production. We propose that the overproduction of sCD14 485 previously observed in macrophages from CF patients (29) should be considered to be a DAMP 486 that can induce pro-inflammatory cytokine/chemokine production independent of LPS. and CF macrophages (n=15, patients 6, 13-26; supplemental Table I ). mRNA levels were 671 determined by RT-qPCR (supplemental Table 2 ). Each symbol represents a single individual, and 672 the line is the mean. (C) Neosynthesis (O.D.) and total (pg/ml) sCD14 in macrophage supernatant 673 from healthy subjects (non-CF, n=5) and CF patients (n=5, patients 6, 13-16, supplemental Table   674 1). The data are shown as the mean ± SEM. Mann-Whitney test: * p<0.05 vs. non-CF 675 macrophages. 6 h 24 h 0 1 10 100 500 sCD14 (ng/ml) Control sCD14 100 ng/ml sCD14 500 ng/ml Control sCD14 100 ng/ml sCD14 500 ng/ml 
